Drug Trial Radar · NCT07449156
A Study to Evaluate Efficacy and Safety of HB0043 in Aadult Patients With Moderate to Severe Acne Vulgaris.
Last checked: Nov 19, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
21
Planned (sponsor's estimate)
Start
Mar 27, 2026
Primary completion
Oct 27, 2026
Study completion Mar 27, 2027
Sponsor
- Lead sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Dermatology Hospital affiliated to Shandong First Medical University
- First posted
- Mar 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single (care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess efficacy safety and tolerability of HB0043 in adult patients with moderate to severe AV.
Conditions
- Acne Vulgaris
Interventions
HB0043Drug
300mg
PlaceboDrug
300mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in inflammatory lesion countsTime frame: Week 16
- Investigator's global assessment (IGA) - change from BaselineTime frame: Week 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dermatology Hospital affiliated to Shandong First Medical University,
Jinan, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.